Accepted for Publication: September 29, 2020.
Published Online: March 4, 2021. doi:10.1001/jamaoncol.2020.7468
Corresponding Author: Icro Meattini, MD, Department of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Viale Morgagni 50, 50134 Florence, Italy (icro.meattini@unifi.it).
Author Contributions: Dr Meattini had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Meattini and Poortmans contributed equally to the work.
Concept and design: Meattini, Poortmans, Cardinale, Lenihan, Marrazzo, Curigliano, Livi.
Acquisition, analysis, or interpretation of data: Meattini, Poortmans, Aznar, Becherini, Bonzano, Curigliano.
Drafting of the manuscript: Meattini, Poortmans, Aznar, Becherini, Bonzano, Cardinale, Marrazzo, Curigliano.
Critical revision of the manuscript for important intellectual content: Meattini, Poortmans, Aznar, Becherini, Cardinale, Lenihan, Marrazzo, Curigliano, Livi.
Administrative, technical, or material support: Meattini, Poortmans, Aznar, Becherini, Curigliano.
Supervision: Meattini, Poortmans, Cardinale, Lenihan, Curigliano, Livi.
Other - bibliographic research and manuscript writing, figures and tables: Marrazzo.
Other: Curigliano.
Conflict of Interest Disclosures: Dr Meattini reported serving on the advisory boards of Lilly, Pfizer, Roche, and Novartis outside the submitted work. Dr Poortmans reported being a medical advisor for Sordina IORT Technologies SpA. Dr Aznar reported receiving grants from the National Institute for Health Research Manchester Biomedical Research Centre and from the Cancer Research UK RadNet Manchester during the conduct of the study. Dr Lenihan reported receiving grants from Myocardial Solutions Inc outside the submitted work. Dr Marrazzo reported receiving financial support from Elekta to participate in the European Society for Radiotherapy and Oncology Congress. Dr Curigliano reported receiving grants from Merck and other from Roche, Novartis, Daiichi Sankyo, AstraZeneca, Lilly, Pfizer, Merck, BMS, and Ellipsis outside the submitted work. No other disclosures were reported.
Additional Contributions: Katherine Jones, MSc, The Christie NHS Foundation Trust; Giorgio Cartechini, MSc, University of Trento; and Marco Schwarz, MSc, PhD, Proton Therapy Center, provided permission to reprint the images in figures 2 and 3. These individuals received no additional compensation, outside of their usual salary, for their contributions.
1.Gilchrist
SC , Barac
A , Ades
PA ,
et al; American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association.
Circulation. 2019;139(21):e997-e1012. doi:
10.1161/CIR.0000000000000679
PubMedGoogle ScholarCrossref 3.Virani
SS , Alonso
A , Benjamin
EJ ,
et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2020 update: a report from the American Heart Association.
Circulation. 2020;141(9):e139-e596. doi:
10.1161/CIR.0000000000000757
PubMedGoogle ScholarCrossref 8.Clarke
M , Collins
R , Darby
S ,
et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
Lancet. 2005;366(9503):2087-2106. doi:
10.1016/S0140-6736(05)67887-7
PubMedGoogle ScholarCrossref 9.Darby
S , McGale
P , Correa
C ,
et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Lancet. 2011;378(9804):1707-1716. doi:
10.1016/S0140-6736(11)61629-2
PubMedGoogle ScholarCrossref 15.Yamamori
T , Yasui
H , Yamazumi
M ,
et al. Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint.
Free Radic Biol Med. 2012;53(2):260-270. doi:
10.1016/j.freeradbiomed.2012.04.033
PubMedGoogle ScholarCrossref 16.Viczenczova
C , Kura
B , Egan Benova
T ,
et al. Irradiation-induced cardiac connexin-43 and miR-21 responses are hampered by treatment with atorvastatin and aspirin.
Int J Mol Sci. 2018;19(4):E1128. doi:
10.3390/ijms19041128
PubMedGoogle Scholar 23.Yu
AF , Ho
AY , Braunstein
LZ ,
et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy.
J Am Soc Echocardiogr. 2019;32(4):521-528. doi:
10.1016/j.echo.2018.12.009
PubMedGoogle ScholarCrossref 26.Skyttä
T , Tuohinen
S , Boman
E , Virtanen
V , Raatikainen
P , Kellokumpu-Lehtinen
PL . Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy.
Radiat Oncol. 2015;10:141. doi:
10.1186/s13014-015-0436-2
PubMedGoogle ScholarCrossref 27.D’Errico
MP , Grimaldi
L , Petruzzelli
MF ,
et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer.
Int J Radiat Oncol Biol Phys. 2012;82(2):e239-e246. doi:
10.1016/j.ijrobp.2011.03.058
PubMedGoogle ScholarCrossref 28.Aula
H , Skyttä
T , Tuohinen
S ,
et al. ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer.
Breast. 2020;49:183-186. doi:
10.1016/j.breast.2019.12.001
PubMedGoogle ScholarCrossref 29.Rutqvist
LE , Lax
I , Fornander
T , Johansson
H . Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer.
Int J Radiat Oncol Biol Phys. 1992;22(5):887-896. doi:
10.1016/0360-3016(92)90784-F
PubMedGoogle ScholarCrossref 31.Houghton
J , Baum
M , Haybittle
JL ; The Closed Trials Working Party of the CRC Breast Cancer Trials Group. Role of radiotherapy following total mastectomy in patients with early breast cancer.
World J Surg. 1994;18(1):117-122. doi:
10.1007/BF00348201
PubMedGoogle ScholarCrossref 32.Højris
I , Overgaard
M , Christensen
JJ , Overgaard
J ; Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials.
Lancet. 1999;354(9188):1425-1430. doi:
10.1016/S0140-6736(99)02245-X
PubMedGoogle ScholarCrossref 34.Halyard
MY , Pisansky
TM , Dueck
AC ,
et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III Trial N9831.
J Clin Oncol. 2009;27(16):2638-2644. doi:
10.1200/JCO.2008.17.9549
PubMedGoogle ScholarCrossref 35.Killander
F , Anderson
H , Kjellén
E , Malmström
P . Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy--25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group.
Eur J Cancer. 2014;50(13):2201-2210. doi:
10.1016/j.ejca.2014.04.033
PubMedGoogle ScholarCrossref 37.Poortmans
PM , Collette
S , Kirkove
C ,
et al; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer.
N Engl J Med. 2015;373(4):317-327. doi:
10.1056/NEJMoa1415369
PubMedGoogle ScholarCrossref 39.Jacob
S , Camilleri
J , Derreumaux
S ,
et al. Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study).
Radiat Oncol. 2019;14(1):29. doi:
10.1186/s13014-019-1234-z
PubMedGoogle ScholarCrossref 40.Taylor
C , Correa
C , Duane
FK ,
et al; Early Breast Cancer Trialists’ Collaborative Group. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials.
J Clin Oncol. 2017;35(15):1641-1649. doi:
10.1200/JCO.2016.72.0722
PubMedGoogle ScholarCrossref 41.van den Bogaard
VA , Ta
BD , van der Schaaf
A ,
et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures.
J Clin Oncol. 2017;35(11):1171-1178. doi:
10.1200/JCO.2016.69.8480
PubMedGoogle ScholarCrossref 43.Pierce
LJ , Feng
M , Griffith
KA ,
et al; Michigan Radiation Oncology Quality Consortium. Recent time trends and predictors of heart dose from breast radiation therapy in a large quality consortium of radiation oncology practices.
Int J Radiat Oncol Biol Phys. 2017;99(5):1154-1161. doi:
10.1016/j.ijrobp.2017.07.022
PubMedGoogle ScholarCrossref 45.Balaji
K , Balaji Subramanian
S , Sathiya
K , Thirunavukarasu
M , Anu Radha
C , Ramasubramanian
V . Hybrid planning techniques for hypofractionated whole-breast irradiation using flattening filter-free beams.
Strahlenther Onkol. 2020;196(4):376-385. doi:
10.1007/s00066-019-01555-1
PubMedGoogle ScholarCrossref 47.Mukesh
MB , Barnett
GC , Wilkinson
JS ,
et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis.
J Clin Oncol. 2013;31(36):4488-4495. doi:
10.1200/JCO.2013.49.7842
PubMedGoogle ScholarCrossref 49.Haciislamoglu
E , Colak
F , Canyilmaz
E ,
et al. Dosimetric comparison of left-sided whole-breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and volumetric arc therapy.
Phys Med. 2015;31(4):360-367. doi:
10.1016/j.ejmp.2015.02.005
PubMedGoogle ScholarCrossref 50.Jin
GH , Chen
LX , Deng
XW , Liu
XW , Huang
Y , Huang
XB . A comparative dosimetric study for treating left-sided breast cancer for small breast size using five different radiotherapy techniques: conventional tangential field, filed-in-filed, tangential-IMRT, multi-beam IMRT and VMAT.
Radiat Oncol. 2013;8:89. doi:
10.1186/1748-717X-8-89
PubMedGoogle ScholarCrossref 52.Taylor
CW , Wang
Z , Macaulay
E , Jagsi
R , Duane
F , Darby
SC . Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013.
Int J Radiat Oncol Biol Phys. 2015;93(4):845-853. doi:
10.1016/j.ijrobp.2015.07.2292
PubMedGoogle ScholarCrossref 53.Murray Brunt
A , Haviland
JS , Wheatley
DA ,
et al; FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Lancet. 2020;395(10237):1613-1626. doi:
10.1016/S0140-6736(20)30932-6
PubMedGoogle ScholarCrossref 57.Lakosi
F , Gulyban
A , Simoni
SB ,
et al. The influence of treatment position (prone vs. supine) on clip displacement, seroma, tumor bed and partial breast target volumes: comparative study.
Pathol Oncol Res. 2016;22(3):493-500. doi:
10.1007/s12253-015-0028-3
PubMedGoogle ScholarCrossref 58.Rodgers
B , Jaroszewski
DE , Ashman
JB , Rule
WG , Sio
TT , Keole
SR . Advantages of post-mastectomy proton beam therapy in a breast cancer patient with pectus excavatum.
J Med Cases. 2017;8(3):98-101. doi:
10.14740/jmc2781w
Google ScholarCrossref 59.DeCesaris
CM , Rice
SR , Bentzen
SM , Jatczak
J , Mishra
MV , Nichols
EM . Quantification of acute skin toxicities in patients with breast cancer undergoing adjuvant proton versus photon radiation therapy: a single institutional experience.
Int J Radiat Oncol Biol Phys. 2019;104(5):1084-1090. doi:
10.1016/j.ijrobp.2019.04.015
PubMedGoogle ScholarCrossref 60.Galland-Girodet
S , Pashtan
I , MacDonald
SM ,
et al. Long-term cosmetic outcomes and toxicities of proton beam therapy compared with photon-based 3-dimensional conformal accelerated partial-breast irradiation: a phase 1 trial.
Int J Radiat Oncol Biol Phys. 2014;90(3):493-500. doi:
10.1016/j.ijrobp.2014.04.008
PubMedGoogle ScholarCrossref 61.Appelt
AL , Vogelius
IR , Bentzen
SM . Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.
Clin Oncol (R Coll Radiol). 2013;25(3):147-152. doi:
10.1016/j.clon.2012.07.012
PubMedGoogle ScholarCrossref 62.Haviland
JS , Owen
JR , Dewar
JA ,
et al; START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Lancet Oncol. 2013;14(11):1086-1094. doi:
10.1016/S1470-2045(13)70386-3PubMedGoogle ScholarCrossref 65.Hughes
KS , Schnaper
LA , Bellon
JR ,
et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
J Clin Oncol. 2013;31(19):2382-2387. doi:
10.1200/JCO.2012.45.2615
PubMedGoogle ScholarCrossref 67.Vicini
FA , Cecchini
RS , White
JR ,
et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Lancet. 2019;394(10215):2155-2164. doi:
10.1016/S0140-6736(19)32514-0
PubMedGoogle ScholarCrossref 68.Strnad
V , Ott
OJ , Hildebrandt
G ,
et al; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.
Lancet. 2016;387(10015):229-238. doi:
10.1016/S0140-6736(15)00471-7
PubMedGoogle ScholarCrossref 69.Coles
CE , Griffin
CL , Kirby
AM ,
et al; IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet. 2017;390(10099):1048-1060. doi:
10.1016/S0140-6736(17)31145-5
PubMedGoogle ScholarCrossref 70.Meattini
I , Marrazzo
L , Saieva
C ,
et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence Trial.
J Clin Oncol. 2020;38(35):4175-4183. doi:
10.1200/JCO.20.00650
PubMedGoogle ScholarCrossref 74.Yu
JM , Hsieh
MC , Qin
L , Zhang
J , Wu
SY . Metformin reduces radiation-induced cardiac toxicity risk in patients having breast cancer.
Am J Cancer Res. 2019;9(5):1017-1026.
PubMedGoogle Scholar